Clinical Trials on Advanced Malignant Pleural Mesothelioma

Total 1055 results

National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Kantonsspital Winterthur KSW

Completed

Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program

Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Urothelial Carcinoma | Pleural Mesothelioma | Gastro-Intestinal Cancer

Switzerland
Jonsson Comprehensive Cancer Center

Recruiting

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers (FAPI PET RDRC)

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Hepatocellular Carcinoma | Cholangiocarcinoma | Cervical Carcinoma | Urothelial Carcinoma | Bladder Carcinoma | Thyroid Gland Carcinoma | Neuroendocrine Neoplasm | Malignant Skin Neoplasm | Malignant Brain Neoplasm | Cancer of Unknown Primary... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

Sarcoma | Lymphoma | Small Cell Lung Carcinoma | Thymic Carcinoma | Thymoma | Mesothelioma | Esophageal Carcinoma | Thyroid Gland Carcinoma | Metastatic Malignant Neoplasm in the Lung | Hypopharyngeal Carcinoma | Laryngeal Carcinoma | Non-Small Cell Lung Carcinoma | Metastatic Malignant Neoplasm in the Pleura | Metastatic...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Metastatic Malignant Neoplasm in the Liver | Advanced Malignant Neoplasm | Refractory Malignant Neoplasm | Colorectal Carcinoma Metastatic in the Liver

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)

Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)

China
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Ovarian Carcinoma | Pancreatic Neuroendocrine Tumor | Unresectable Solid Neoplasm | Fibrolamellar Carcinoma

United States
Institut Bergonié
Bayer; Merck KGaA, Darmstadt, Germany

Recruiting

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)

Hepatocellular Carcinoma | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Soft-tissue Sarcoma | Urothelial Carcinoma | Thyroid Cancer | Gastro-enteropancreatic Neuroendocrine Tumor | Biliary Tract Cancer | HPV-Related Carcinoma | Solid Tumor, Adult | Mesotheliomas Pleural | GIST | Renal Carcinoma | Colorectal... and other conditions

France
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage... and other conditions
Calithera Biosciences, Inc

Withdrawn

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Lymphoma, Malignant | Advanced Solid Neoplasms

United States
AstraZeneca

Completed

Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

Advanced Solid Malignancies | Malignant Lymphoma

United Kingdom, Japan
Istituto Scientifico Romagnolo per lo Studio e...

Completed

Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer (GastroDOC)

Gastric Cancer | Locally Advanced Malignant Neoplasm

Italy
Mayo Clinic

Recruiting

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Multiple Myeloma | Myelodysplastic Syndrome | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Hematopoietic and Lymphoid System Neoplasm | Advanced Lung Carcinoma | Advanced Prostate Carcinoma | Advanced Glioblastoma | Advanced Gastric Carcinoma | Advanced Breast Carcinoma | Advanced Colorectal... and other conditions

United States
Shanghai Yuyao Biotech Co., Ltd.

Recruiting

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Advanced Solid Tumor | Hematological Malignancy

China
National Cancer Institute (NCI)

Withdrawn

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
Amgen

Completed

AMG 595 First-in-Human in Recurrent Gliomas

Glioblastoma Multiforme | Advanced Malignant Glioma | Anaplastic Astrocytomas

United States, Australia
Akeso

Not yet recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114

Metastasis | Advanced or Metastatic Solid Tumors | Malignancy

Australia
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
Kartos Therapeutics, Inc.
GlaxoSmithKline

Completed

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Melanoma | Cancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology Patients

United States, Australia
National Cancer Institute (NCI)

Active, not recruiting

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor

United States
Constellation Pharmaceuticals

Not yet recruiting

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Solid Tumor | Hematologic Malignancy | Advanced Malignancies
Constellation Pharmaceuticals

Completed

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

Solid Tumor | Advanced Malignancies | Hematological Malignancy

Spain, United States, Georgia
M.D. Anderson Cancer Center

Completed

Bevacizumab and Bortezomib in Patients With Advanced Malignancy

Lymphoma | Solid Tumors | Myeloma | Advanced Malignancy

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm

United States
Mirati Therapeutics Inc.

Recruiting

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Metastatic Cancer | Advanced Cancer | Malignant Neoplastic Disease

United States, Puerto Rico
St Vincent's University Hospital, Ireland

Recruiting

A Contemporary Review of Surgical Approaches in Pelvic Exenterative Surgery

Locally Advanced Rectal Cancer | Pelvic Exenteration | Advanced Pelvic Malignancy

Ireland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Brain Neoplasm | Refractory Brain Neoplasm

United States
Helsinki University Central Hospital

Recruiting

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)

Solid Tumor | Advanced Cancer | Haematological Malignancy

Finland
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Communication Training for Caregivers In Advanced Care Planning

Advanced Care Planning | Primary Malignant Brain Tumors

United States
Chinese Medical Doctor Association

Unknown

The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey (Sprit)

Colorectal Cancer | Advanced Malignant Neoplasm

China
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Withdrawn

Testing the Safety of CB-5339 in Patients With Cancer

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal

Melanoma | Sarcoma | Pleural Malignancy | Epithelial Malignancies

United States
Morphotek

Terminated

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Melanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic Melanoma

United States
Assistance Publique - Hôpitaux de Paris
Federation Francophone de Cancerologie Digestive; UNICANCER; Merck Serono S.A... and other collaborators

Unknown

Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer (ECKINOXE)

Colon Cancer | Locally Advanced Malignant Neoplasm

France
Cancer Institute and Hospital, Chinese Academy...

Unknown

Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer

Locally Advanced Malignant Neoplasm

China

Clinical Trials on Advanced Malignant Pleural Mesothelioma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations